C反应蛋白/白蛋白比值与接受膝下血管内治疗的慢性肢体威胁性缺血患者长期死亡率的相关性:ACHILES-BTK注册研究
本研究纳入172例因膝下病变行血管内治疗的慢性肢体威胁性缺血患者,随访32±21个月,40.6%死亡。死亡组C反应蛋白/白蛋白比值显著高于存活组(9.75 vs 3.25,P<0.001),且该比值是全因死亡的独立预测因素。
要点
- 死亡组C反应蛋白/白蛋白比值显著高于存活组(9.75 vs 3.25,P<0.001)。
- C反应蛋白/白蛋白比值、充血性心力衰竭、慢性肾脏病、卒中史、ACE抑制剂/血管紧张素受体拮抗剂或他汀使用是全因死亡的独立预测因素。
- C反应蛋白/白蛋白比值或有助于血管内治疗的患者选择、评估和干预策略。
核心结论
- C反应蛋白/白蛋白比值与接受膝下病变血管内治疗的慢性肢体威胁性缺血患者死亡率相关。
- C反应蛋白/白蛋白比值可能是一种简单的方法,有助于血管内治疗的患者选择、评估和干预策略,并可能改善患者结局。
研究设计与样本
- 研究纳入172例因膝下病变接受血管内治疗的慢性肢体威胁性缺血患者。
- 排除需要抗生素治疗的急性感染、慢性炎症性疾病、终末期肝病、恶性肿瘤以及同一血管床随访前干预的患者。
- 主要终点为全因死亡率,患者按死亡与否分为2组。
主要发现
- 随访32±21个月期间,70例患者(40.6%)死亡。
- 大截肢率为21.5%。
- 死亡组年龄更大,充血性心力衰竭、慢性肾脏病、卒中史和C反应蛋白水平更高。
- 死亡组他汀和ACE抑制剂/血管紧张素受体拮抗剂使用率、肾小球滤过率和白蛋白水平更低。
- 死亡组C反应蛋白/白蛋白比值显著高于存活组(9.75 [4.5-17.71] vs 3.25 [1.46-7.86],P<0.001)。
关键数值与推荐
- 多变量Cox回归分析显示,C反应蛋白/白蛋白比值、充血性心力衰竭、慢性肾脏病、卒中史、ACE抑制剂/血管紧张素受体拮抗剂或他汀使用是全因死亡的独立预测因素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic limb-threatening ischemia (CLTI), which presents with ischemic rest pain, ulceration, or gangrene, is a complex form of peripheral artery disease that can cause mortality and amputation. C-reactive protein (CRP), an inflammatory marker, indicates vascular inflammation resulting from the cytokine-dependent inflammatory process in the arterial wall, and arterial atherosclerosis resulting from the inflammation. Lower albumin levels are also associated with peripheral artery disease. We investigated the association between CRP/Albumin ratio (CAR) and long-term mortality in patients with CLTI. METHODS: A total of 172 patients who underwent endovascular treatment (EVT) for below the knee (BTK) lesions were enrolled in this study. Patients with acute infection requiring antibiotic therapy, chronic inflammatory disease, end-stage liver disease, malignancy were excluded from the study. Besides, patients with pre-follow-up intervention to the same vascular bed were also excluded from the study. The primary endpoint of the study was all-cause mortality. Patients were divided into 2 groups according to mortality. RESULTS: A total of 70 patients (40.6%) died during 32 ± 21 months of follow-up in the present study. The major amputation rate was 21.5%. The mortality (+) group was older and had higher rates of congestive heart failure, chronic kidney disease, history of stroke, and CRP levels. Moreover, statin and ACE inhibitor/angiotensin receptor blocker (ACE/ARB) use, GFR, and albumin levels were lower in the mortality (+) group. CAR was significantly higher in the mortality (+) group when comparing both groups (3.25 [1.46 - 7.86] vs. 9.75 [4.5 - 17.71], P < 0.001). CAR, congestive heart failure, chronic kidney disease, history of stroke, ACE/ARB, or statin use were independent predictors of all-cause mortality in multivariable Cox regression analysis. CONCLUSIONS: CAR was associated with mortality in CLTI patients undergoing EVT for BTK lesions. CAR may be a simple method to help patient selection, assessment, and intervention strategy for EVT and may improve patient outcomes.
引用
- Panç C, Güler A, Gürbak İ, et al. Association Between CRP/Albumin Ratio and Long-Term Mortality in Patients With cHronIc Limb-Threatening Ischemia Undergoing EndovaScular Therapy Below The Knee: The ACHILES-BTK Registry. Ann Vasc Surg. 2021. PMID: 34896550. doi:10.1016/j.avsg.2021.11.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。